Company: TAK
Filing Date: 2025-06-25
Form Type: 20-F
Source: 0001395064-25-000095
Chunk: 261

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-06-25
Form: 20-F
Item: Item 19
Chunk 261
---
 the following:

• Integration of Shire - In the year ended March 31, 2023, Takeda directed various restructuring efforts following the Shire acquisition. The integration of Shire includes initiatives to consolidate systems, sites, and functions, and to optimize the workforce.

• Enterprise-wide efficiency program - Takeda implemented an enterprise-wide program in the fiscal year ended March 31, 2025, aimed at promoting business growth and improving profitability. This program includes increasing the agility and simplicity of our business organization, investing in digital, data, and technology to enhance productivity and efficiency across the organization, and implementing cost reductions and process improvements in supply chain and vendor management.

• Various other efforts to improve the efficiency of its operations and related facilities.

A restructuring provision is recorded when Takeda has developed a detailed formal plan for the restructuring and, through an execution of the plan or an announcement of its main features to those affected by it, a valid expectation has been raised in those affected by the plan that the plan will be implemented. Takeda records the provision and associated expenses based on estimated costs associated with the plan. The ultimate cost and the timing of any payments under the plan will be impacted by the actual timing of the actions and the actions of employees impacted by the restructuring activities.

Restructuring expenses recorded for the fiscal years ended March 31, 2023, 2024 and 2025 are as follows:

                                   JPY (millions)                                                    
                                   For the Year Ended March 31                                       
                                   2023                                                              
 ─────────────────────────────────────────────────────────────────────────────────────────────────────
  Cash:                                                                                              
  Severance                        ¥                                10,605      13,685       62,595  
  Consulting fees                                                   12,709      11,528       16,205  
  Other                                                             33,601      48,622       44,784  
  Total                            ¥                                56,915      73,835      123,584  
  Non-Cash:                                                                                          
  Depreciation and impairment      ¥                                 2,320       7,523        4,548  
  Total                            ¥                                59,234      81,358      128,133  

Other restructuring expenses for the fiscal years ended March 31, 2023, 2024 and 2025 include personnel expenses of JPY 9,683 9,769 16,353

F-53

digital transformation